Dofetilide: A new drug to control cardiac arrhythmia

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 973-985

  Elming, Hanne ^a   Brendorp, Bente ^b   Pedersen, Ole Dyg ^b   Køber, Lars ^a   Torp Petersen, Christian ^c  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Antiarrhythmic agent; Atrial fibrillation; Dofetilide; Mortality; Torsade de pointes

Indexed keywords

AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; ENCAINIDE; ERYTHROMYCIN; FLECAINIDE; GATIFLOXACIN; IBUTILIDE; LEVOFLOXACIN; MORACIZINE; MOXIFLOXACIN; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SPARFLOXACIN; TAMOXIFEN; TIZANIDINE; UNINDEXED DRUG;

AGING; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LONG QT SYNDROME; LUNG TOXICITY; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; THYROID DISEASE; VALVULAR HEART DISEASE; WESTERN HEMISPHERE;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CLINICAL TRIALS; HUMANS; PHENETHYLAMINES; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONAMIDES; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 0038344648     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.973     Document Type: Review

References (60)

1. RYDER KM, BENJAMIN EJ et al.: Epidemiology and significance of atrial fibrillation. Am. J. Cardiol. (1999) 84:131R-138R.
2. BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840-844.
3. LEVY S, MAAREK M, COUMEL P et al.: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation (1999) 99:3028-3035.
4. FUSTER V, RYDEN LE, ASINGER RW et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart. J. (2001) 22:1852-1923.
5. TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New Engl. J. Med (1999) 341:857-865.
6. KOBER L, BLOCH THOMSEN PE, MOLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356:2052-2058.
7. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandingrian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. (1987) 316:1429-1435.
8. MARU M: Atrial fibrillation and embolic complications. East Afr. Med. J. (1997) 74:3-5.
9. BENJAMIN EJ, WOLF PA, D'AGOSTINO RB et al.: Impact of atrial fibrillation on the risk of death. the Framingham Heart Study. Circulation (1998) 98:946-952.
10. WYSE DG, LOVE JC, YAO Q et al.: Atrial fibrillation: a risk factor for increased mortality-an AVID registry analysis. J. Interv. Card Electrophysiol. (2001) 5:267-273.
11. PEDERSEN OD, BAGGER H, KOBER L et al.: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. Trandolapril Cardiac Evaluation. Eur.Heart. J. (1999) 20:748-754.
12. HAMER ME, BLUMENTHAL JA, MCCARTHY EA et al.: Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am. J. Cardiol. (1994) 74:826-829.
13. WYSE DG, WALDO AL, DIMARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
14. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation (1991) 84:1831-1851.
15. COPLEN SE, ANTMAN EM, BERLIN JA et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation (1990) 82:1106-1116.
16. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cast investigators Cardiac Arrhythmia Suppression Trial (CAST). N. Engl. J. Med. (1989) 321(6):406-412.
17. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N. Engl. J. Med. (1992) 327:227-233.
18. JUUL-MOLLER S, EDVARDSSON N, REHNQVIST-AHLBERG N et al.: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation (1990) 82:1932-1939.
19. THIBAULT B, NATTEL S: Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J. Cardiovasc. Electrophysiol. (1999) 10:472-481.
20. WALDO AL, CAMM AJ, DERUYTER H et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral D-sotalol. Lancet (1996) 348:7-12.
21. SUNDT TM 3rd, CAMILLO CJ, COX JL et al: The maze procedure for cure of atrial fibrillation. Cardiol. Clin. (1997) 15:739-748.
22. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data ftom 6500 patients in randomised trials. Amiodarone trials meta-analysis investigators. Lancet (1997) 350:1417-1424.
23. GWILT M, ARROWSMITH JE, BLACKBURN KJ et al.: UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther. (1991) 256:318-324.
24. SEDGWICK ML, RASMUSSEN HS, COBBE SM et al.: Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am. J. Cardiol. (1992) 69:513-517.
25. SINGH S, ZOBLE RG, YELLEN L et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385-2390.
26. RASMUSSEN HS, ALLEN MJ, BLACKBURN KJ, BUTROUS GS, DALRYMPLE HW et al.: Dofetilide, a novel class III antiarrhythmic agent. J. Cardiovasc. Pharmacol. (1992) 20(Suppl. 2):S96-S105.
27. GWILT M, DALRYMPLE HW, BURGES RA et al.: Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J. Cardiovasc. Pharmacol. (1991) 17:376-385.
28. + current by dofetilide. Circ. Res (1993) 72:75-83.
29. ROUSSEAU MF, MASSART PE, VAN EYLL C et al.: Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am. J. Cardiol. (2001) 87:1250-1254.
30. BORIANI G, BIFFI M, BACCHI L et al.: A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. Eur. J. Clin. Pharmacol. (2002) 58:165-169.
31. TWEEDIE D, HENDERSON C, KANE K et al.: Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. J. Pharmacol. (1993) 240:251-257.
32. ANDERSEN HR, WIGGERS H, KNUDSEN LL et al.: Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs. Cardiovasc. Res. (1994) 28:1635-1640.
33. KNILANS TK LATHROP DA, NANASI PP et al.: Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax. Br. J. Pharmacol. (1991) 103:1568-1572.
34. SEDGWICK ML, RASMUSSEN HS, COBBE SM et aL.: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am. J. Cardiol. (1992) 70-1432-1437.
35. LE COZ F, FUNCK-BRENTANO C, MORELL T et al.: Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin. Pharmacol. Ther. (1995) 57:533-542.
36. SMITH DA, RASMUSSEN HS, STOPHER. DA et al.: Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica (1992) 22:709-719.
37. GEMMILL JD, HOWIE CA, MEREDITH PA et al.: A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br. J. Clin. Pharmacol. (1991) 32:429-432.
38. WALKER DK, ALABASTER CT, CONGRAVE GS et al.: Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab. Dispos. (1996) 24:447-455.
39. GREENBAUM RA. CAMBELL TJ, CHANNE KS: EMERALD. Circulation (1998) 17:633-633 (Abstract).
40. PEDERSEN OD, BAGGER H, KELLER N et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation (2001) 104:292-296.
41. TENDERA M, WNUK-WOJNAR AM, KULAKOWSKI P et al.: Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am. Heart (2001) 142:93-98.
42. POOL PE, SINGH SN, FRIEDRICH T et al.: Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial. Clin. Cardiol. (2000) 23:415-416.
43. BASHIR Y, THOMSEN PE, KINGMA JH et al.: Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am. J. Cardiol (1995) 76:1040-1044.
44. ECHT DS, LEE JT, MURRAY KT et al.: A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophysiol. (1995) 6:687-699.
45. BORIANI G, LUBINSKI A, CAPUCCI A et al.: A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide versus sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur. Heart J. (2001) 22:2180-2191.
46. MAZUR A, ANDERSON ME, BONNEY S,RODEN DM et al.: Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J. Am. Coll. Cardiol. (2001) 37:1100-1105.
47. BRENDORP B, ELMING H, JUN L et al.: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation (2001) 103:1422-1427.
48. PRITCHETT EL, WILKINSON WE: Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am. Heart J. (1999) 138:994-997.
49. KÖBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor randolapril in patients with left ventricular Dysfunction After Myocardial Infarction. N. Engl. J. Med. (1995) 333:1670-1676.
50. Pfizer Laboratories: Tikosyn′ (dofetilide) Package insert. Pfizer Laboratories (1999).
51. LAPOINTE NM, KRAMER JM, WEINFURT KP, CALIFF RM et al.: Practitioner acceptance of the dofetilide risk-management program. Pharmacotherapy (2002) 22:1041-1046.
52. BRENDORP B, ELMING H, JUN L et al.: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrthythmic treatment with dofetilide. Circulation (2001) 103:1422-1427.
53. CRIJNS HJ, VAN GELDER IC, KINGMA JH et al.: Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur. Heart J. (1994) 15:1403-1408.
54. SEDGWICK ML, LIP G, RAE AP, COBBE SM et al.: Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int. J. Cardiol. (1995) 49:159-166.
55. FROST L, MORTENSEN PE, TINGLEFF J et al.: Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int. J. Cardiol. (1997) 58:135-140.
56. FALK RH, POLLAK A, SINGH SN, FRIEDRICH T et al.: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J. Am. Coll. Cardiol. (1997) 29:385-390.
57. NORGAARD BL, WACHTELL K, CHRISTENSEN PD et al.: Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J. (1999) 137:1062-1069.
58. LINDEBOOM JE, KINGMA JH, CRIJNS HJ, DUNSELMAN PH et al.: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am. J. Cardiol. (2000) 85:1031-1033.
59. BIANCONI I, CASTRO A, DINELLI M et al.: Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur. Heart J. (2000) 21:1265-1273.
60. COBBE SM, CAMPBELL RW, CAMM AJ et al.: Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart (2001) 86:522-526.